The Global Health Body Raises Warning Over Severe Lack of Obesity Injections

Less than 10% of individuals who could benefit from weight-loss injections like Wegovy can access them, states the global health agency as it issues its first guidance on the medications.

Given over a billion people worldwide currently obese, it is urging broader and more equitable access to this class of drugs.

Per projections, more than two billion will be obese by 2030 unless action is taken.

"Our latest guidance acknowledges that excess weight is a lifelong illness that can be treated with comprehensive and continuous treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and logistical bottlenecks are major hurdles to widespread availability to the jabs that can help people shift significant body mass, notes the organization.

Skinny Jab Supply Crisis

Despite the present most optimistic case, the production of GLP-1 therapies might only reach approximately 100 million people – less than 10% of the global need, as stated by the health organization.

The recommendation encourages nations and manufacturers to expand availability, through measures like licensing agreements.

Exclusive production rights on a key compound – the primary component of a leading brand – is due to expire in several nations in 2026.

The Way Obesity Injections Function

GLP-1 drugs mimick a natural hormone to reduce digestion speed, reduce hunger and increase satiety so individuals reduce food intake.

Individuals usually begin shedding pounds within a few weeks of starting on the once-weekly jabs.

Research suggests users may regain a significant portion after a year of halting the treatment, when their normal food cravings return.

To be overweight or obese raises your chance for developing medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and specific cancers.

Obesity affects people in countries worldwide and was associated with 3.7 million fatalities worldwide in 2024, as per the health agency.